Ann Pediatr Endocrinol Metab.  2024 Feb;29(1):3-11. 10.6065/apem.2346206.103.

An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database)

• Geffner ME
• Ranke MB
• Wajnrajch MP
• for the Pfizer International Growth Database Strategic Executive Committee, Strategic Advisory Board, and International Board

• KMID: 2553012
• DOI: http://doi.org/10.6065/apem.2346206.103

Abstract

The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.

Keyword

Kabi International Growth Study; Pharmaco-epidemiological study; Recombinant human growth hormone